



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/003,211-Conf. #6970
				Filing Date	October 31, 2001
				First Named Inventor	Jeffrey L. BROWNING
				Art Unit	1642
				Examiner Name	C. H. Yaen
Sheet	1	of	1	Attorney Docket Number	BGNA013CN

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
ICYI	A1*	US-6,403,087	06-11-2002	Browning et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Christopher Yaen/ (04/30/2007)	Date Considered	04/30/2007
-----------------------	--------------------------------	--------------------	------------

Copies of references were filed with the parent case, S/N 09/299,139, and can be found in that file.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

A01:

Application Number

09/299,139

Applicant(s)

Browning et al.

Filing Date

April 23, 1999

Group Art Unit

1642

JCS 3 U.S. PTO
10/00321



EXAMINER INITIAL	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
CY	CO Duzgunesa et al., Q514:77, "Liposome Targeting TO HIV-Infected Cells Via Recombinant Soluble CD4 And CD4-IgG (Immunoadhesin)" NO DATE
CY	CP Endres et al., 1999, J. of Med., 189:159-167, "Mature Follicular Dendritic Cell Networks Depend on Expression Of Lymphotoxin Beta Receptor By Radioresistant Stromal Cells And Of Lymphotoxin Beta And Tumor Necrosis Factor By B Cells"
CY	CQ Eppstein et al., 1985, Proc. Natl. Acad. Sci., 82:3688-3692, "Biological Activity Of Liposome-Encapsulated Murine Interferon Gamma Is Mediated By A Cell Membrane Receptor"
CY	CR Erickson et al., 1994, Nature, 372:560-563, "Decreased Sensitivity To Tumour-Necrosis Factor But Normal T-cell Development In TNF Receptor-2-Deficient Mice"
CY	CS Ettinger et al., 1996, Proc. Natl. Acad., 93:13102-13107, "Disrupted Splenic Architecture, But Normal Lymph Node Development In Mice Expressing A Soluble Lymphotoxin-Beta Receptor-IgG1 Fusion Protein"
CY	CT Fitch et al., 1993, Annu. Rev. Immunol., 11:29-48, "Differential Regulation Of Murine Lymphocyte Subsets"
CY	CU Force et al., 1995, American Association of Immunol., 5280-5288, "Mouse Lymphotoxin-Beta Receptor"
CY	CV Foy et al., 1994, J. Exp. Med., 180:157-163, "gp39-CD40 Interactions Are Essential For Germinal Center Formation and the Development of B Cell Memory"
CY	CW Fu, Chaplin, et al., 1999, Annu. Rev. Immunol., 17:399-433, "Development and Maturation of Secondary Lymphoid Tissues"
CY	CX Fu, Huang, et al., 1998, J. Exp. Med., 187:1009-1018, "B Lymphocytes Induce the Formation of Follicular Dendritic Cell Clusters in a Lymphotoxin-Alpha-Dependent Fashion"
CY	CY Fu, Molina, et al., 1997, J. Exp. Med., 185:2111-2120, Lymphotoxin-Alpha (LTa) Supports Development of Splenic Follicular Structure That Is Required for IgG Responses"
CY	CZ Futterer et al., 1998, Immunity, 9:59-70, "The Lymphotoxin Beta Receptor Controls Organogenesis and Affinity Maturation in Peripheral Lymphoid Tissues"

EXAMINER

C. Yac

DATE CONSIDERED

8.30.04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.